{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T17:07:36Z","timestamp":1755796056090},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2009,12,10]],"date-time":"2009-12-10T00:00:00Z","timestamp":1260403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2009,12,10]],"date-time":"2009-12-10T00:00:00Z","timestamp":1260403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1007\/s10637-009-9365-y","type":"journal-article","created":{"date-parts":[[2009,12,9]],"date-time":"2009-12-09T05:25:14Z","timestamp":1260336314000},"page":"374-379","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["A phase II study of everolimus in combination with imatinib for previously treated advanced renal carcinoma"],"prefix":"10.1007","volume":"29","author":[{"given":"Christopher W.","family":"Ryan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline","family":"Vuky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph S.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zunqiu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomasz M.","family":"Beer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deirdre","family":"Nauman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,12,10]]},"reference":[{"key":"9365_CR1","doi-asserted-by":"publisher","first-page":"6290S","DOI":"10.1158\/1078-0432.CCR-sup-040025","volume":"10","author":"WG Kaelin Jr","year":"2004","unstructured":"Kaelin WG Jr (2004) The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin Cancer Res 10:6290S\u20136295S","journal-title":"Clin Cancer Res"},{"key":"9365_CR2","doi-asserted-by":"publisher","first-page":"7004","DOI":"10.1128\/MCB.22.20.7004-7014.2002","volume":"22","author":"CC Hudson","year":"2002","unstructured":"Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, Kaper F, Giaccia AJ, Abraham RT (2002) Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 22:7004\u20137014","journal-title":"Mol Cell Biol"},{"key":"9365_CR3","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa066838","volume":"356","author":"G Hudes","year":"2007","unstructured":"Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271\u20132281. doi:356\/22\/2271 [pii] 10.1056\/NEJMoa066838","journal-title":"N Engl J Med"},{"key":"9365_CR4","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","volume":"372","author":"RJ Motzer","year":"2008","unstructured":"Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372:449\u2013456. doi:S0140-6736(08)61039-9 [pii] 10.1016\/S0140-6736(08)61039-9","journal-title":"Lancet"},{"key":"9365_CR5","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S0065-230X(06)97011-0","volume":"97","author":"A Ostman","year":"2007","unstructured":"Ostman A, Heldin CH (2007) PDGF Receptors as Targets in Tumor Treatment. Adv Cancer Res 97:247\u2013274. doi:S0065-230X(06)97011-0 [pii] 10.1016\/S0065-230X(06)97011-0","journal-title":"Adv Cancer Res"},{"key":"9365_CR6","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1309\/LQ9EMK8QKE75NGGX","volume":"120","author":"I Sulzbacher","year":"2003","unstructured":"Sulzbacher I, Birner P, Traxler M, Marberger M, Haitel A (2003) Expression of platelet-derived growth factor-alpha alpha receptor is associated with tumor progression in clear cell renal cell carcinoma. Am J Clin Pathol 120:107\u2013112. doi:10.1309\/LQ9E-MK8Q-KE75-NGGX","journal-title":"Am J Clin Pathol"},{"key":"9365_CR7","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031\u20131037","journal-title":"N Engl J Med"},{"key":"9365_CR8","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s10637-005-4543-z","volume":"24","author":"J Vuky","year":"2006","unstructured":"Vuky J, Isacson C, Fotoohi M, dela Cruz J, Otero H, Picozzi V, Malpass T, Aboulafia D, Jacobs A (2006) Phase II trial of imatinib (Gleevec) in patients with metastatic renal cell carcinoma. Invest New Drugs 24:85\u201388. doi:10.1007\/s10637-005-4543-z","journal-title":"Invest New Drugs"},{"key":"9365_CR9","doi-asserted-by":"publisher","first-page":"427","DOI":"10.3816\/CGC.2007.n.030","volume":"5","author":"Hainsworth JD, Spigel DR, Sosman JA, Burris HA, 3rd, Farley C, Cucullu H, Yost K, Hart LL, Sylvester L, Waterhouse DM and Greco FA","year":"2007","unstructured":"Hainsworth JD, Spigel DR, Sosman JA, Burris HA, 3rd, Farley C, Cucullu H, Yost K, Hart LL, Sylvester L, Waterhouse DM and Greco FA (2007) Treatment of advanced renal cell carcinoma with the combination bevacizumab\/erlotinib\/imatinib: a phase I\/II trial. Clin Genitourin Cancer 5:427\u2013432","journal-title":"Clin Genitourin Cancer"},{"key":"9365_CR10","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3816\/CGC.2006.n.007","volume":"4","author":"BN Polite","year":"2006","unstructured":"Polite BN, Desai AA, Manchen B, Stadler WM (2006) Combination therapy of imatinib mesylate and interferon-alpha demonstrates minimal activity and significant toxicity in metastatic renal cell carcinoma: results of a single- institution phase II trial. Clin Genitourin Cancer 4:275\u2013280","journal-title":"Clin Genitourin Cancer"},{"key":"9365_CR11","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1172\/JCI17929","volume":"111","author":"G Bergers","year":"2003","unstructured":"Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D (2003) Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111:1287\u20131295. doi:10.1172\/JCI17929","journal-title":"J Clin Invest"},{"key":"9365_CR12","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1158\/1078-0432.CCR-08-2057","volume":"15","author":"HA Lane","year":"2009","unstructured":"Lane HA, Wood JM, McSheehy PM, Allegrini PR, Boulay A, Brueggen J, Littlewood-Evans A, Maira SM, Martiny-Baron G, Schnell CR, Sini P, O'Reilly T (2009) mTOR inhibitor RAD001 (everolimus) has antiangiogenic\/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin Cancer Res 15:1612\u20131622. doi:1078-0432.CCR-08-2057 [pii] 10.1158\/1078-0432.CCR-08-2057","journal-title":"Clin Cancer Res"},{"key":"9365_CR13","doi-asserted-by":"crossref","first-page":"9033","DOI":"10.1200\/jco.2005.23.16_suppl.9033","volume":"23","author":"A van oosterom","year":"2005","unstructured":"van oosterom A, Reichardt P, Blay J-Y, Dumez H, Fletcher J, Debiec-Rychter M, Shand N, Drimitrijevic S, Yap A, Demetri g (2005) A phase I\/II trial of the oral mTOR-inhibitor everolimus (E) and imatinib mesylate (IM) in patients (pts) with gastrointestinalstromal tumor (GIST) refractory to IM: Study update. J Clin Oncol 23:9033","journal-title":"J Clin Oncol"},{"key":"9365_CR14","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"9365_CR15","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa060655","volume":"356","author":"B Escudier","year":"2007","unstructured":"Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM (2007) Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma. N Engl J Med 356:125\u2013134","journal-title":"N Engl J Med"},{"key":"9365_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1\u201310. doi:0197-2456(89)90015-9 [pii]","journal-title":"Control Clin Trials"},{"key":"9365_CR17","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1200\/JCO.2004.06.132","volume":"22","author":"RJ Motzer","year":"2004","unstructured":"Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S, Mazumdar M (2004) Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22:454\u2013463","journal-title":"J Clin Oncol"},{"key":"9365_CR18","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1056\/NEJMoa020461","volume":"347","author":"GD Demetri","year":"2002","unstructured":"Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472\u2013480. doi:10.1056\/NEJMoa020461 347\/7\/472 [pii]","journal-title":"N Engl J Med"},{"key":"9365_CR19","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1097\/00007890-200504270-00020","volume":"79","author":"U Fuchs","year":"2005","unstructured":"Fuchs U, Zittermann A, Berthold HK, Tenderich G, Deyerling KW, Minami K, Koerfer R (2005) Immunosuppressive therapy with everolimus can be associated with potentially life-threatening lingual angioedema. Transplantation 79:981\u2013983. doi:00007890-200504270-00020 [pii]","journal-title":"Transplantation"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-009-9365-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-009-9365-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-009-9365-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-009-9365-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:49:48Z","timestamp":1678510188000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-009-9365-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12,10]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["9365"],"URL":"https:\/\/doi.org\/10.1007\/s10637-009-9365-y","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12,10]]},"assertion":[{"value":"9 October 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2009","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2009","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}